-The Times of India As many as 2,644 people, called subjects, died during the clinical trials of 475 new drugs on human beings in last seven years and only 17 of the medicines were approved for marketing in India, the Centre has informed the Supreme Court. Responding to allegations by NGO, Swasthya Adhikar Manch, in its PIL that Indians were used as guinea pigs by foreign pharmaceutical majors for human trial of...
More »SEARCH RESULT
Total Matching Records found : 1258
Dr Purnima Menon, research fellow at the IFPRI's Poverty, Health and Nutrition Division interviewed by Shobha Warrier
-Rediff.com Recently, a study on India's State Hunger Index comparing hunger across all India states was released by Purnima Menon, Anil Deolalikar and Anjor Bhaskar. Dr Purnima Menon is a research fellow at the International Food Policy Research Institute's Poverty, Health and Nutrition Division, and is based at IFPRI's Asia office in New Delhi. She conducts applied nutrition research in the South Asia region, with a focus on programs and policies to improve...
More »Centre for incentivising use of clean energy, says Montek
-The Hindu Says potential and implications of shale gas policy need to be examined The government was all for creating a viable and competitive domestic production base and incentivise use of clean energy in the country, Deputy Chairman of the Planning Commission Montek Singh Ahluwalia said at the fourth Clean Energy Ministerial here on Wednesday. Efforts were on to encourage domestic production and usage. "We are interested in incentivising the use of...
More »Social Justice
KEY TRENDS • According to National Sample Survey report no. 583: Persons with Disabilities in India, the percentage of persons with disability who received aid/help from Government was 21.8 percent, 1.8 percent received aid/help from organisation other than Government and another 76.4 percent did not receive aid/ help *8 • As per National Family Health Survey-4 (NFHS-4), the Under-five Mortality Rate (U5MR) was 57.2 per 1,000 live births (for the non-STs it was 38.5)...
More »Why Novartis case will help innovation-Achal Prabhala and Sudhir Krishnaswamy
-The Hindu The Supreme Court judgment on Glivec is a blow for a patent regime with a higher threshold of inventiveness On April 1, 2013, the Supreme Court upheld the Intellectual Property Appellate Board's decision to deny patent protection to Novartis's application covering a beta crystalline form of imatinib -the medicine Novartis brands as Glivec, and which is very effective against the form of cancer known as chronic myeloid leukaemia (CML). The...
More »
